Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24648736 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL15244828 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL26039743 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL5873425 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL12966021 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL31421469 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL5873415 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL7398961 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL20061841 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL9371448 | 0.87 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462637-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1558248-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050054704-A1 | Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-6852748-B1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2004041273-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054704-A1 | Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide | ARG1, HPGDS, MIF | SMN1; SMN2 2456/4885ALDH1A1 1222/4885KMT2A 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.